RMD Resmed Loading... : Bullish and Bearish Analyst Opinions
Loading chart...
Top Calls
Feed
12:26
Aug 07
Aug 07
US pre-market movers show strong gains for NET, ABNB, MCHP, TEAM, CART, MP.
US pre-market movers show strong gains for NET, ABNB, MCHP, TEAM, CART, MP, and DV on earnings or acquisition news, while RMD, TTD, and SG decline on misses or guidance cuts.
20:30
Aug 06
Aug 06
Management provided a positive outlook for fiscal year 2027, focusing on core business growth, gross margin expansion, and a significant return of capital to shareholders, despite the headwind from the ASTRAL recall.
HIGH
01:05
Jul 04
Jul 04
Morgan Stanley downgrades ResMed; speaker lists the action with no specific bearish thesis.
Morgan Stanley downgrades ResMed; speaker lists the action with no specific bearish thesis or mechanism provided for this name.
MED
11:56
Jun 17
Jun 17
SpaceX rises 1.9% premarket, Figma gains 4.2% on Citi buy rating.
SpaceX rises 1.9% premarket, Figma gains 4.2% on Citi buy rating, La-Z-Boy jumps 16% on earnings beat, ResMed slips 1% on Morgan Stanley downgrade, and Rexford Industrial falls 1.4% on JPMorgan underweight cut.
16:10
May 07
May 07
Short ResMed as the short leg of a GLP-1 pair trade.
Short ResMed as the short leg of a GLP-1 pair trade; GLP-1-driven weight loss reduces sleep apnea prevalence, structurally undermining demand for CPAP devices.
MED
20:15
May 04
May 04
The tweet simply tags ResMed as a follow-up ticker without providing any directional opinion.
The tweet simply tags ResMed as a follow-up ticker without providing any directional opinion or market analysis.
HIGH
00:57
May 01
May 01
Bearish view on RMD as CFO departure on top of decelerating US device sales.
Bearish view on RMD as CFO departure on top of decelerating US device sales, even on the easiest year-over-year comparison, signals underlying operational weakness.
HIGH
00:40
May 01
May 01
The CFO's retirement amid slowing US device sales signals potential internal turmoil.
The CFO's retirement amid slowing US device sales signals potential internal turmoil and weakening demand for ResMed's core products.
HIGH
00:19
May 01
May 01
Bearish view on medtech stocks/ETF as the speaker expects further multiples compression.
Bearish view on medtech stocks/ETF as the speaker expects further multiples compression tomorrow, driven by a directional bearish view on the sector's valuation.
HIGH
20:30
Apr 30
Apr 30
Management reaffirmed its confidence in the long-term outlook for high single-digit revenue growth with earnings growing faster than revenue, driven by operational excellence, gross margin expansion, and a robust pipeline of innovation, even amidst global geopolitical uncertainty.
HIGH
14:49
Apr 27
Apr 27
Short RMD due to GLP-1-driven CPAP attrition, slowing growth into FY27.
Short RMD due to GLP-1-driven CPAP attrition, slowing growth into FY27, and no multi-product floor for a single-product medtech.
HIGH
11:43
Apr 22
Apr 22
Bearish view on DXCM, RMD, and ISRG because accelerating declines in bariatric procedures.
Bearish view on DXCM, RMD, and ISRG because accelerating declines in bariatric procedures for ISRG signal that GLP-1 drugs are reducing demand for related medical devices and services, extending to diabetes management and respiratory care.
HIGH
11:42
Apr 22
Apr 22
Bearish view on DXCM and RMD because accelerating declines in bariatric procedures due to GLP-1.
Bearish view on DXCM and RMD because accelerating declines in bariatric procedures due to GLP-1 drug adoption signal a structural headwind for companies exposed to obesity and diabetes-related treatment demand.
HIGH
21:30
Jan 29
Jan 29
Management maintains strong growth and margin expansion, with continued confidence in supply chain efficiencies and demand generation.
HIGH
About RMD Analyst Coverage
Buzzberg tracks RMD (Resmed) across 6 sources. 0 bullish vs 2 bearish calls from 7 analysts. Sentiment: mixed to bearish. 14 total trade ideas tracked. Latest voices: Newsquawk, Mick Farrell, asklivermore.